NCT07251595

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR0302 Tablets as Single Therapy or in Combination With SHR0302 Base Gel in the Treatment of Patients With Non-segmental Vitiligo

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.

Conditions

• Non-segmental Vitiligo

Interventions

Type	Name	Description
DRUG	SHR0302 Tablets	SHR0302 tablets.
DRUG	SHR0302 Base Gel	SHR0302 Base gel.
DRUG	SHR0302 Placebo Tablets	SHR0302 placebo tablets.
DRUG	SHR0302 Base Placebo Gel	SHR0302 Base placebo gel.

Timeline

• Start date: 2025-12-05
• Primary completion: 2027-03-01
• Completion: 2027-09-01
• First posted: 2025-11-26
• Last updated: 2026-02-18

Locations

1 site across 1 country: China